Gilead’s twice-a-year injection fully prevented HIV in Phase 3 study with cisgender women

There were no cases of HIV in over 2,000 cisgender women who received a twice-a-year preventive HIV injection developed by Gilead as part of a Phase 3 clinical trial.

The data, announced Thursday morning, led an independent data review group to recommend that the company stop the blinded study and offer the prevention treatment to all participants.

The PURPOSE 1 study showed that there was a lower incidence of HIV cases with the twice-a-year injection of lenacapavir compared to data on background HIV incidence, as well as compared to Truvada, Gilead’s daily pill that’s used for prevention.

“It’ll be a game changer for people who are at high risk, as long as implementing it doesn’t become a huge problem,” said Rachel Presti, a professor of infectious diseases at the Washington University School of Medicine in St. Louis. She was not involved in the study.

The results…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks